Investment Rating - The report maintains a "Buy" rating for the company, indicating expected returns exceeding the market benchmark by more than 15% over the next 6-12 months [6]. Core Views - The company achieved a revenue of 13.585 billion yuan in 2024, a year-on-year increase of 67.60%, and a net profit attributable to shareholders of 2.173 billion yuan, up 52.57% year-on-year [4]. - The domestic gold price rose from 481.2 yuan per gram at the beginning of the year to 615.02 yuan per gram by year-end, marking an increase of 27.81% [4]. - The company’s gold production is expected to increase, with a projected output of 8.04 tons in 2024, a 14.69% year-on-year growth, contributing to revenue of 4.423 billion yuan, up 34.07% [5]. - The company is accelerating its international expansion, having completed the acquisition of Osino, adding 127.2 tons of gold resources, with an expected annual production capacity of 5 tons post-production [5]. Financial Summary - The company forecasts revenues of 15.893 billion yuan in 2025, 17.559 billion yuan in 2026, and 19.527 billion yuan in 2027, with respective year-on-year growth rates of 17.0%, 10.5%, and 11.2% [8]. - The net profit attributable to shareholders is projected to be 3.307 billion yuan in 2025, 4.079 billion yuan in 2026, and 4.977 billion yuan in 2027, with year-on-year growth rates of 52.2%, 23.3%, and 22.0% respectively [8]. - The gross margin is expected to improve from 29.9% in 2024 to 43.4% by 2027 [8].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 928 million yuan in 2024, a year-on-year decrease of 5.97%, and a net profit attributable to shareholders of 56 million yuan, down 64.56% year-on-year [5][9] - The fourth quarter saw continued pressure on product prices and rising raw material costs, leading to a decline in overall revenue and profit [5][6] - The PEKK material is expected to ramp up production, providing a new growth driver for the company [7][9] Summary by Sections Financial Performance - In 2024, the company achieved a revenue of 928 million yuan, with a year-on-year decline of 6.0% expected for 2025 [10] - The net profit attributable to shareholders is projected to be 80 million yuan in 2025, reflecting a year-on-year growth of 42.6% [10] - The gross margin for 2024 is reported at 23.0%, with a slight decrease expected in the following years [10] Product and Market Analysis - The demand for chlorosulfonic acid and related products has been lower than expected due to a sluggish pesticide market, impacting pricing and profitability [6] - The company has successfully developed a one-step production method for PEKK, which is expected to enhance its competitive edge in the market [7] Future Outlook - The company is expected to see a gradual recovery in net profit, with projections of 127 million yuan in 2026 and 187 million yuan in 2027, indicating a strong growth trajectory [9][10] - The expansion into high-performance polymer materials and the development of new products are anticipated to support future revenue growth [8][9]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 928 million yuan in 2024, a year-on-year decrease of 5.97%, and a net profit attributable to shareholders of 56 million yuan, down 64.56% year-on-year [4][5] - The fourth quarter saw continued pressure on product prices and rising raw material costs, leading to a decline in overall revenue and profit [5][6] - The PEKK material is expected to ramp up production, providing a new growth driver for the company [7][9] Summary by Sections Financial Performance - In 2024, the company achieved a revenue of 928 million yuan, with a year-on-year decline of 6.0% expected for 2025, followed by growth of 27.5% in 2026 and 13.6% in 2027 [10] - The net profit attributable to shareholders is projected to be 80 million yuan in 2025, 127 million yuan in 2026, and 187 million yuan in 2027, with corresponding year-on-year growth rates of 42.6%, 59.7%, and 47.1% respectively [10] Product and Market Insights - The company is a leading player in chlorosulfonic acid and is expanding its product line into high-performance polymer materials such as PEKK [8][9] - The PEKK material has significant performance advantages and is crucial for national strategic development, with the company achieving a cost advantage through its production process [7] Future Outlook - The company is expected to see a gradual recovery in profits as it continues to innovate and expand its product offerings, particularly in the PEKK segment [9] - The projected net profit for 2025-2027 indicates a positive growth trajectory, with the company aiming to leverage its technological advancements and market position [9][10]

[Table_StockNameRptType] 金融工程 周报 ⚫ 跟踪近期打新收益率 跟踪近期科创板+创业板+主板的网下打新市场表现，假设所有主 板、科创板、创业板的股票都打中，且上市首日以市场均价卖出，忽 略锁定期的卖出限制，自 2025 起截至 2025/3/14，A 类 2 亿规模账户 打新收益率 0.71%，C 类 2 亿规模账户打新收益率 0.61%；A 类 10 亿规模账户打新收益率 0.17%，C 类 10 亿规模账户打新收益率 0.13%。 打新账户数出现回升趋势 ——"打新定期跟踪"系列之二百零七 滚动跟踪近期 20 只新股上市后的涨幅表现，其中科创板个股上 市首日平均涨幅为 192.07%，创业板个股上市首日平均涨幅为 381.09%。 [Table_RptDate] 报告日期：2025-03-17 滚动跟踪近期 20 只新股的有效报价账户中位数，目前科创板新 股 A 类有效报价账户数量在 2975 左右，C 类有效报价账户数量在 1876 右。创业板新股 A 类有效报价账户数量在 3112 左右，C 类有效 报价账户数量在 2011 左右。主板个股 A 类有效报价账户数量在 3379 ...

Investment Rating - The industry investment rating is "Overweight" [1] Core Views - The chemical sector's overall performance ranked 19th with a fluctuation of 1.59% during the week of March 8-14, 2025, outperforming the Shanghai Composite Index by 0.19 percentage points and the ChiNext Index by 0.61 percentage points [3][26] - The report highlights a continued trend of divergence in the chemical industry in 2025, recommending attention to sectors such as synthetic biology, pesticides, chromatography media, sweeteners, vitamins, light hydrocarbon chemicals, COC polymers, and MDI [4] Summary by Sections Industry Review - The chemical sector's performance for the week was 1.59%, with the top three performing sub-sectors being nitrogen fertilizers (5.16%), oil and gas refining (4.63%), and synthetic resins (4.55%) [26][27] - The top three individual stocks in the chemical sector were Kexin New Source (26.5%), Aoyang Health (18.1%), and Nuofeng (16.0%) [32] Supply-Side Tracking - A total of 136 companies in the chemical industry had their production capacities affected, with 7 new maintenance cases and 3 restarts reported [15] Key Industry Dynamics - The report notes the imminent implementation of quota policies for third-generation refrigerants, which are expected to enter a high prosperity cycle due to supply constraints and stable demand growth from markets like heat pumps and cold chains [5] - The electronic specialty gases market is highlighted as a critical area for domestic substitution opportunities, driven by rapid upgrades in downstream industries such as integrated circuits and photovoltaics [6][8] - The light hydrocarbon chemical trend is identified as a global movement, with a shift towards lighter raw materials for olefin production, which is expected to enhance the value of leading companies in this sector [8] - The COC polymer industry is experiencing accelerated domestic industrialization, with significant breakthroughs in production capabilities and increasing demand from various applications [9] - The potassium fertilizer market is anticipated to rebound as major suppliers reduce production and inventory pressures ease, with a recommendation to focus on leading companies in this field [10] - The MDI market is characterized by oligopoly, with a favorable supply structure expected to improve as demand recovers, making it a resilient chemical product through economic cycles [13]

[Table_IndNameRptType] 基础化工 行业点评 代糖行业格局向好，产品价格有望开启向上周期 主要观点： [⚫Table_Summary] 事件描述 2 月 16 日，金禾实业、科宏生物、康宝生化和新琪安科技等四家三 氯蔗糖主力生产企业召开三氯蔗糖峰会，巩固联盟，共谋协同发展。 据百川，3 月 10 日起三氯蔗糖主力生产企业集体封盘不报，三氯蔗 糖贸易商低位惜售，部分报价已上涨 0.5-0.8 万元/吨，多数有跟随封 单操作。3月13日三氯蔗糖最新价格维持在25万元/吨，同比+100%， 较年初+4.17%；2024 年 9 月金禾实业发布调价函，安赛蜜价格从 3.4 万元/吨提高至 3.9 万元/吨，而后略有下降，3 月 14 日安赛蜜价 格为 3.7 万元/吨，同比-2.63%，较年初保持一致。 ⚫ 三氯蔗糖厂商协同发展，安赛蜜有望复刻三氯蔗糖涨价逻辑 三氯蔗糖市场高度集中于金禾实业（1.3 万吨）、科宏生物（0.8 万吨）、 康宝生化（0.8 万吨）和新琪安科技（0.3 万吨）四家主力企业中， CR4 为 91.95%。据百川，截至 2025 年 3 月，我国三氯蔗糖产能约 有 3.48 ...

Investment Rating - Industry rating: Overweight [1] Core Insights - The offshore wind projects are progressing steadily, and photovoltaic module prices have increased again [1] - The photovoltaic sector is expected to benefit from a recovery in fundamentals and gradual policy implementation, approaching a right-side startup phase [20] - The energy storage sector is seeing unexpected growth in demand for lithium batteries used in data centers, with a focus on data centers and storage PCS segments [24] - The hydrogen energy industry is accelerating development due to strong policy support and increased investment and mergers within the sector [35] - The construction of high-voltage direct current (HVDC) projects is expected to maintain a high level of prosperity in 2025, with significant opportunities in the ultra-high voltage sector [39] Summary by Sections Photovoltaics - N-type module prices increased by 0.02 CNY/W, driven by demand from 430 and 531 projects, with production ramping up in March [12][19] - The photovoltaic sector's performance tracked a 1.67% increase, outperforming the market [12] - The industry is expected to see a price recovery in Q1 2025, with a focus on companies capable of navigating through cycles [20] Wind Power - The wind power sector saw a 2.53% increase, outperforming the market, with a significant rise in new installations in 2023 [21] - The market sentiment is boosted by the unexpected commencement of offshore wind projects, with a focus on tower and foundation segments [21] - Investment recommendations include undervalued stocks and those benefiting from offshore wind projects [21] Energy Storage - The energy storage sector is witnessing a robust demand for lithium batteries, particularly in data centers, with a focus on improving profitability models [24][30] - Notable growth in energy storage sales and margins reported by leading companies like CATL [24] - Various provinces are enhancing their energy storage subsidy policies, indicating a supportive environment for growth [25][26] Hydrogen Energy - Multiple provinces are actively promoting hydrogen energy development, with significant investments and mergers accelerating within the industry [35][37] - The establishment of hydrogen production and storage projects is gaining momentum, with a focus on comprehensive hydrogen energy ecosystems [36] - The market is expected to see a restructuring of the hydrogen energy landscape due to major transactions and strategic partnerships [37] Electric Grid Equipment - The commencement of the Gansu-Zhejiang ±800 kV HVDC project is a key development, with expectations of high demand for related equipment [39][40] - The construction of high-voltage transmission lines is projected to enhance the clean energy utilization capacity in the northwest region [39] - Investment recommendations focus on undervalued companies in the electric grid sector, particularly those involved in ultra-high voltage projects [39] Electric Vehicles - Domestic policies are focusing on consumption upgrades and technological industries, with initiatives to promote the replacement of old vehicles [41][42] - The automotive sector is expected to benefit from government support for electric vehicle upgrades and new energy vehicle development [41][44]

D [Table_IndNameRptType] 基础化工 行业周报 合成生物学周报：苏州发布加快推动生物制造产业发 展行动计划，美国 FDA 拟取消 self-GRAS 条款 [Table_IndRank] 行业评级：增持 报告日期： 2025-03-16 [Table_Chart] 行业指数与沪深 300 走势比较 -28% -17% -6% 6% 17% 28% 3/24 6/24 9/24 12/24 基础化工 沪深300 [Table_Author] 分析师：王强峰 执业证书号：S0010522110002 电话：13621792701 邮箱：wangqf@hazq.com 分析师：刘天其 执业证书号：S0010524080003 电话：17321190296 邮箱：liutq@hazq.com 主要观点： [Table_Summary] 华安证券化工团队发表的《合成生物学周报》是一份面向一级市场、 二级市场，汇总国内外合成生物学相关领域企业信息的行业周报。 目前生命科学基础前沿研究持续活跃，生物技术革命浪潮席卷全球并 加速融入经济社会发展，为人类应对生命健康、气候变化、资源能源 安全、粮食安全等重 ...

Investment Rating - The industry investment rating is "Overweight" [1] Core Views - The report highlights the ongoing global biotechnology revolution, which is actively integrating into economic and social development, providing innovative solutions to major challenges such as health, climate change, resource security, and food security. The National Development and Reform Commission has issued the "14th Five-Year Plan for Bioeconomic Development," indicating a trillion-yuan market potential in the bioeconomy [3][4]. Summary by Sections 1. Industry Market Performance - The synthetic biology sector saw a decline of 4.83% in the week of March 10-14, 2025, ranking 32nd among various sectors [15]. - The Huazhong Synthetic Biology Index dropped to 1364.84, underperforming compared to the Shanghai Composite Index by 6.22 percentage points [4][15]. 2. Company Business Developments - Sinopec's bio-based polyethylene products have successfully been exported to Japan, marking a breakthrough in international trade [22]. - SF Express signed a bulk purchase agreement for sustainable aviation fuel (SAF) with Sinopec Hong Kong, aiming to reduce costs and improve logistics [22]. - Shanghai Huide Technology established a company focused on bio-based materials, expanding its production scale and integrating resources [24]. - Toray Industries announced that it will use a mass balance method in producing acrylic fibers, achieving ISCC PLUS certification [24]. - SK Energy signed a contract to supply over 20,000 tons of SAF to Cathay Pacific by 2027, furthering its commitment to sustainable fuel production [25]. 3. Industry Financing Tracking - The synthetic biology sector is experiencing accelerated financing, with nearly a hundred companies completing new rounds of financing since the beginning of 2025 [31]. - Xin Hai Bio announced a strategic investment from Sinochem Capital, enhancing its capabilities in enzyme preparations and chiral chemicals [32]. - Epoch Biodesign secured $18.3 million in Series A funding to develop a facility for enzyme-based nylon recycling [32]. 4. Industry Research and Development Directions - Shenzhen Qimei achieved a breakthrough in separating cellulose from straw, which is expected to significantly improve resource utilization and reduce environmental pollution [35].

医药生物 分析师：谭国超 执业证书号：S0010521120002 邮箱：tangc@hazq.com 分析师：陈珈蔚 执业证书号： S0010524030001 邮箱： chenjw@hazq.com 联系人：刘洪飞 执业证书号：S0010123080001 邮箱：liuhongfei@hazq.com 相关报告 1.行业周报：看好具备成长和估值相 得益彰的医药标的 2024-03-04 2.行业周报：医药本周回调较大，需 要关注"中药+创新落地的品类" 2024-03-11 3.行业周报：医药板块处于底部位 置，建议加大对医药的配置 2024- 07-01 行业周报 辅助生殖政策量变引发市场关注，医药板块持续活跃 行业评级：增持 报告日期： 2024-03-16 4.行业周报：AI 破局医药板块 2025- 02-16 5.行业周报：创新板块接力 AI 破局 2025-02-23 主要观点： 本周行情回顾：板块上涨 本周医药生物指数上涨 1.77%，跑赢沪深 300 指数 0.18 个百分 点，跑赢上证综指 0.37 个百分点，行业涨跌幅排名第 15。3 月 14 日 （本周五），医药生物行业 PE（TT ...